This is a platform study to investigate the effectiveness of a variety of non-prescription approaches for the treatment of non-hospitalized adults recently tested positive for COVID-19.
This study will screen for the activity of a variety of non-prescription approaches for the
treatment of non-hospitalized adults recently diagnosed with COVID-19. This will be a
randomized, blinded placebo-controlled study with respect to the active treatment (chlorine
dioxide) vs placebo, and randomized open-label with respect to a non-prescription medication
(famotidine) and supplements including zinc, EGCG and lactoferrin. Treatment will last for 7
days.
Other: chlorine dioxide
chlorine dioxide is an antimicrobial agent used for a variety of purposes including as a water purification product, a disinfectant on food, etc.
Dietary Supplement: zinc acetate
zinc acetate lozenges have been suggested to have antiviral properties
Drug: Famotidine
famoitidine is a histamine-2 blocker sold over the counter to reduce stomach acid
Other Name: Pepcid
Other: placebo
filtered water
Other Name: filtered water
Dietary Supplement: lactoferrin, green tea extract
lactoferrin and green tea extract are dietary supplements
Inclusion Criteria:
1. Signed and dated informed consent form
2. Stated willingness to comply with all study procedures and availability for the
duration of the study
3. Male or female, aged 20-70
4. Confirmed diagnosis of COVID-19 by positive COVID-19 test. Symptoms of a mild degree
such that hospitalization is not required. Within 7 days of symptom onset.
5. Ability to drink at least 1 liter of water daily and be willing to adhere to the study
regimen
Exclusion Criteria:
1. COVID-19 symptoms of a severe enough nature that requires hospitalization
2. Pregnancy or lactation
3. Diagnosis of diabetes mellitus
4. currently taking paroxetine or digoxin
5. Individuals with diabetes mellitus
AZ Good Health Center
Tempe, Arizona, United States
Jonathan Murphy, MD, MD(H), Principal Investigator
Profact, Inc.